Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 12:11:2.
doi: 10.1186/s13023-016-0382-6.

The involvement of patient organisations in rare disease research: a mixed methods study in Australia

Affiliations

The involvement of patient organisations in rare disease research: a mixed methods study in Australia

Deirdre Pinto et al. Orphanet J Rare Dis. .

Abstract

Background: We report here selected findings from a mixed-methods study investigating the role of Australian rare disease patient organisations (RDPOs) in research. Despite there being many examples of RDPOs that have initiated and supported significant scientific advances, there is little information - and none at all in Australia - about RDPOs generally, and their research-related goals, activities, and experiences. This information is a pre-requisite for understanding what RDPOs bring to research and how their involvement could be strengthened.

Methods: We reviewed 112 RDPO websites, conducted an online survey completed by 61 organisational leaders, and interviewed ten leaders and two key informants. Quantitative and qualitative data were analysed using basic descriptive statistics and content analysis, respectively.

Results: Although most are small volunteer-based groups, more than 90% of the surveyed RDPOs had a goal to promote or support research on the diseases affecting their members. Nearly all (95 %) had undertaken at least one research-related activity - such as providing funding or other support to researchers - in the previous five years. However, RDPO leaders reported considerable challenges in meeting their research goals. Difficulties most frequently identified were insufficient RDPO resources, and a perceived lack of researchers interested in studying their diseases. Other concerns included inadequate RDPO expertise in governing research "investments", and difficulty engaging researchers in the organisation's knowledge and ideas. We discuss these perceived challenges in the light of two systemic issues: the proliferation of and lack of collaboration between RDPOs, and the lack of specific governmental policies and resources supporting rare disease research and patient advocacy in Australia.

Conclusion: This study provides unique information about the experiences of RDPOs generally, rather than experiences retrospectively reported by RDPOs associated with successful research. We describe RDPOs' valuable contributions to research, while also providing insights into the difficulties for small organisations trying to promote research. The study is relevant internationally because of what it tells us about RDPOs; however, we draw attention to specific opportunities in Australia to support RDPOs' involvement in research, for the benefit of current and future generations affected by rare diseases.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Age of Australian rare disease patient organisations. The proportion of Australian RDPOs falling into each of six age categories, based on survey responses from 57 RDPO leaders who provided information about the year in which their organisation was formed

Similar articles

Cited by

References

    1. Orphanet. Orphanet website Australia entry point. [Internet] 2013 [cited 2014 29 Dec]; Available from: http://www.orpha.net/national/AU-EN/index/about-rare-diseases/.
    1. European Organisation for Rare Diseases. What is a rare disease? [Internet]. 2013 [cited 2013 Mar 4]; Available from: http://www.eurordis.org/content/what-rare-disease.
    1. Australian Bureau of Statistics [Internet]. 2014 [cited 2014 Dec 29]; Available from: www.abs.gov.au.
    1. Litterman NK, Rhee M, Swinney DC, Ekins S. Collaboration for rare disease drug discovery research. F1000Research. 2014;3:261. - PMC - PubMed
    1. Wästfelt M, Fadeel B, Henter JI. A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med. 2006;260(1):1–10. doi: 10.1111/j.1365-2796.2006.01666.x. - DOI - PubMed